Endovia achieves first FDA regulatory milestone for CannEpil veterinary program

SPLASH BEVERAGE GROUP, INC.

FDA Center for Veterinary Medicine established INAD File No. 14145 for CannEpil development program.
First milestone under collaboration with Lupvindol Biosciences Ltd.; formally initiates FDA regulatory process.
Initial target: management of cancer-related pain in companion animals, starting with canine oncology.
Company intends to pursue FDA Minor Use/Minor Species (MUMS) designation and Conditional Approval pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.